Hormonal
GLP-1RAs exhibit neuroprotective effects and may improve symptoms in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and cognitive dysfunction associated with type 2 diabetes.
For patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes, GLP-1 receptor agonists like semaglutide can significantly reduce heart failure symptoms and improve physical limitations. Additionally, there is emerging evidence that these medications may offer neuroprotective benefits, potentially slowing cognitive decline in patients with T2DM.
a recent STEP-HFpEF trial reported that semaglutide significantly ameliorated heart failure-related symptoms in patients with obesity-related HFpEF and T2DM after one year of treatment... GLP-1RAs exhibit antiproliferative effects on vascular smooth muscle cells and anti-inflammatory actions on macrophages, contributing to the prevention of atherosclerosis development and progression.
Why this rating
Supported by specific RCTs (STEP-HFpEF) and mechanistic studies, but the paper notes that neuroprotective clinical needs are largely unmet and more research is needed.
Source
The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review
Zhao Liu et al. · Drug Design Development and Therapy · 2025
DOI 10.2147/dddt.s559919
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) and dual GLP-1/GIP receptor agonists (e.g., tirzepatide) significantly reduce body weight and improve glycemic control in patients with type 2 diabetes and obesity by stimulating insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite.Strong
- GLP-1RAs confer cardiovascular protection by reducing the risk of major adverse cardiovascular events (MACE), including death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke, particularly in patients with established cardiovascular disease and obesity.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →